New Delhi, Nov. 23 -- Oxford University AstraZeneca vaccine candidate, AZD1222, against coronavirus disease (Covid-19) has shown 70% efficacy on average, according to the newly published data of phase 2/3 clinical trials held in UK and Brazil, the company announced on Monday.

In effect, the results mean that of all the people who get vaccinated, as high as 70% will not get the disease.

Also, experts had tried two different dosing regimens, of which one showed a better profile of close to 90% efficacy.

"Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the ...